Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 14Terminated 2Unknown 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 12Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Advanced Pancreatic Cancer 3Esophageal Neoplasms 2Biliary Tract Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Staging IV NSCLC 1Squamous Cell Carcinoma of Lung 1Solid Tumor 1Sertoli-Leydig Cell Tumor 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Ovarian gynandroblastoma 1Obesity 1Neurotoxicity Syndromes 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Liver Neoplasms 1HER2-negative Breast Cancer 1HER2+ Breast Cancer 1

Interventions

Fluorouracil 3Cyclophosphamide 3pegfilgrastim 2Paclitaxel 2Immunoenzyme Techniques 2Epirubicin 2Chemotherapy, Adjuvant 2Biopsy 2Bevacizumab 2Amplified Fragment Length Polymorphism Analysis 2orantinib 1eribulin 1Zoledronic Acid 1Therapeutics 1Taxes 1Sorafenib 1Radiotherapy 1Radioimmunodetection 1Pyridoxine 1Psychiatric Rehabilitation 1Neoadjuvant Therapy 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunologic Techniques 1Ibandronic Acid 1Gene Rearrangement 1Gene Expression Profiling 1Flow Cytometry 1Drug Screening Assays, Antitumor 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasms, Male × Taxes × Clear all
NCT00436709 2014-01-06

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

National Cancer Institute (NCI)

Phase NA Unknown
75 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡